journal
Journals Lung Cancer : Journal of the I...

Lung Cancer : Journal of the International Association for the Study of Lung Cancer

https://read.qxmd.com/read/38640687/trends-and-predictors-of-quality-of-life-in-lung-cancer-survivors
#1
JOURNAL ARTICLE
Brett C Bade, Julian Zhao, Fangyong Li, Lynn Tanoue, Heather Lazowski, Catherine M Alfano, Gerard A Silvestri, Melinda L Irwin
INTRODUCTION: Health-related quality of life (HR-QoL) is often impaired in lung cancer survivors. To inform personalized survivorship care, we identified associations between HR-QoL scores and patient-, tumor-, and treatment-factors over time. MATERIALS AND METHODS: We evaluated HR-QoL scores provided at diagnosis, 6 months, 1 year, and 2 years from the Yale Lung Cancer Biorepository. HR-QoL was measured via the Functional Assessment of Cancer Therapy - Lung (FACT-L) instrument and available for a subset of patients (n = 513)...
April 16, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38636314/the-cost-effectiveness-of-including-liquid-biopsy-into-molecular-profiling-strategies-for-newly-diagnosed-advanced-non-squamous-non-small-cell-lung-cancer-in-an-asian-population
#2
JOURNAL ARTICLE
Sibo Liu, Nicholas Graves, Aaron C Tan
OBJECTIVES: Liquid biopsy is complementary to tissue biopsy for lung cancer profiling, yet evidence of the cost-effectiveness is limited. This could retard implementation and reimbursement in clinical practice. The aim of this study is to estimate the cost-effectiveness of profiling strategies that include liquid biopsy and to identify the optimal profiling approach for newly diagnosed advanced non-squamous non-small cell lung cancer (NSCLC) in an Asian population using Singapore as an example...
April 15, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38621343/the-optimal-treatment-for-patients-with-stage-i-non-small-cell-lung-cancer-minimally-invasive-lobectomy-versus-stereotactic-ablative-radiotherapy-a-nationwide-cohort-study
#3
JOURNAL ARTICLE
Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink
OBJECTIVES: The aim of the Early-Stage LUNG cancer (ESLUNG) study was to compare outcomes after minimally invasive lobectomy (MIL) and stereotactic ablative radiotherapy (SABR) in patients with stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: In this retrospective cohort study, patients with clinical stage I NSCLC (according to TNM7), treated in 2014-2016 with MIL or SABR, were included. 5-year overall survival (OS) and recurrence-free survival (RFS) were calculated and compared between patients treated with MIL and a propensity score (PS)-weighted SABR population with characteristics comparable to those of the MIL group...
April 12, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38621342/proteomic-profiling-of-tumor-microenvironment-and-prognosis-risk-prediction-in-stage-i-lung-adenocarcinoma
#4
JOURNAL ARTICLE
Yueh-Feng Lu, Ya-Hsuan Chang, Yi-Ju Chen, Min-Shu Hsieh, Mong-Wei Lin, Hsao-Hsun Hsu, Chia-Li Han, Yu-Ju Chen, Sung-Liang Yu, Jin-Shing Chen, Hsuan-Yu Chen
OBJECTIVES: With the increasing popularity of CT screening, more cases of early-stage lung cancer are being diagnosed. However, 24.5% of stage I non-small-cell lung cancer (NSCLC) patients still experience treatment failure post-surgery. Biomarkers to predict lung cancer patients at high risk of recurrence are needed. MATERIALS AND METHODS: We collected protein mass spectrometry data from the Taiwan Lung Cancer Moonshot Project and performed bioinformatics analysis on proteins with differential expressions between tumor and adjacent normal tissues in 74 stage I lung adenocarcinoma (LUAD) cases, aiming to explore the tumor microenvironment related prognostic biomarkers...
April 12, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38614068/management-of-sotorasib-related-adverse-events-and-hepatotoxicities-following-anti-pd-l-1-therapy-experience-with-sotorasib-in-two-french-anti-cancer-centers-and-practical-guidance-proposal
#5
JOURNAL ARTICLE
Ali Chour, Clémence Basse, Fanny Lebossé, Pierre-Emmanuel Bonte, Nicolas Girard, Michaël Duruisseaux
INTRODUCTION: Sotorasib is a first-in-class KRASG12C inhibitor that showed significant clinical activity in KRASG12C -mutated non-small cell lung cancer (NSCLC). The most frequent grade 3 or 4 sotorasib-related adverse events (AEs) were diarrhea (4-12 %) and hepatotoxicity (10.1-15.1 %). Data is lacking about the management of these AEs, especially in patients receiving sequential anti-PD-(L)1 and sotorasib therapy. Our aim was to report the management of grade ≥ 2 sotorasib-related AEs in real-world setting and to propose practical guidance for the management of grade ≥ 2 sotorasib-related AEs and more generally KRASG12C inhibitors-related AEs...
April 9, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38593478/clinical-significance-of-inter-assay-discrepancy-in-pd-l1-evaluation-for-the-efficacy-of-pembrolizumab-in-advanced-nsclc-with-high-pd-l1-expression
#6
JOURNAL ARTICLE
Jun Miyakoshi, Tatsuya Yoshida, Jumpei Kashima, Masayuki Shirasawa, Masahiro Torasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Noboru Yamamoto, Yasushi Yatabe, Takuji Suzuki, Yuichiro Ohe
INTRODUCTION: Programmed cell death ligand-1 (PD-L1) expression is a predictive biomarker for the efficacy of anti-programmed cell death receptor-1/PD-L1 antibodies in advanced non-small cell lung cancer (NSCLC). Although several assays have been approved for evaluating PD-L1 expression status, inter-assay discordance has been observed between some assays. The clinical significance of these discrepancies is still unclear. METHODS: We retrospectively reviewed treatment-naïve NSCLC patients whose PD-L1 expression was evaluated using both 22C3 and SP142 assays...
April 6, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38593479/the-biomarkers-atlas-an-audit-on-1100-non-small-cell-lung-cancer-from-an-italian-knowledge-based-database
#7
JOURNAL ARTICLE
Umberto Malapelle, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Maria Lucia Reale, Diego Cortinovis, Filippo Fraggetta, Domenico Galetta, Edoardo Garbo, Paolo Graziano, Fabio Pagni, Giulia Pasello, Pierluigi Piovano, Sara Pilotto, Marcello Tiseo, Carlo Genova, Luisella Righi, Giancarlo Troncone, Silvia Novello
AIMS: To date, precision medicine has revolutionized the clinical management of Non-Small Cell Lung Cancer (NSCLC). International societies approved a rapidly improved mandatory testing biomarkers panel for the clinical stratification of NSCLC patients, but harmonized procedures are required to optimize the diagnostic workflow. In this context a knowledge-based database (Biomarkers ATLAS, https://biomarkersatlas.com/) was developed by a supervising group of expert pathologists and thoracic oncologists collecting updated clinical and molecular records from about 80 referral Italian institutions...
April 5, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38582025/is-the-onset-of-immune-related-adverse-events-themselves-a-prognostic-factor-or-a-confounding-factor
#8
LETTER
Tadashi Nishimura, Hajime Fujimoto
No abstract text is available yet for this article.
April 4, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38626709/long-term-follow-up-and-exploratory-analysis-of-lenvatinib-in-patients-with-metastatic-or-recurrent-thymic-carcinoma-results-from-the-multicenter-phase-2-remora-trial
#9
JOURNAL ARTICLE
Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto
OBJECTIVES: The main objective of this report was to detail the long-term follow-up data from the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with thymic carcinoma. In addition, an exploratory analysis of the association between relative dose intensity (RDI) and the efficacy of lenvatinib is presented. MATERIALS AND METHODS: The single-arm, open-label, phase 2 REMORA study was conducted at eight Japanese institutions. Forty-two patients received oral lenvatinib 24 mg once daily in 4-week cycles until the occurrence of intolerable adverse events or disease progression...
March 30, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38569279/familial-rare-egfr-mutant-lung-cancer-syndrome-review-of-literature-and-description-of-r776h-family
#10
REVIEW
L Gabriel, T McVeigh, S Macmahon, Z Avila, L Donovan, I Hunt, A Draper, A Minchom, S Popat, M Davidson, J Bhosle, C Milner Watts, M Hubank, L Yuan, Mer O'Brien
BACKGROUND: Interest in hereditary lung cancer is increasing, in particular germline mutations in the Epidermal Growth Factor Receptor (EGFR) gene. We review the current literature on this topic, discuss risk of developing lung cancer, treatment and screening options and describe a family of 3 sisters with lung cancer and their unaffected mother all with a rare EGFR germline mutation (EGFR p.R776H). METHODS: We searched PubMed, Medline, Embase, the Cochrane Library, Google Scholar and scanned reference lists of articles...
March 30, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38569278/spatiotemporal-distribution-of-mediastinal-neoplasms-a-comprehensive-multi-center-study
#11
JOURNAL ARTICLE
Yu Jiang, Yuechun Lin, Chao Yang, Ping He, Zhichao Liu, Haixuan Wang, Ran Zhong, Linchong Huang, Zhigang Li, Fuhao Xu, Xu Lin, Jun Liu, Xin Xu, Shuben Li, Fei Cui, Wei Wang, Wenhua Liang, Lei Zhao, Jian Hu, Bin Li, Donglai Chen, Wenfang Tang, Chun Chen, Junke Fu, Xuefeng Leng, Dazhi Pang, Jianxing He, Hengrui Liang
OBJECTIVES: Mediastinal neoplasms are typical but uncommon thoracic diseases with increasing incidence and unfavorable prognoses. A comprehensive understanding of their spatiotemporal distribution is essential for accurate diagnosis and timely treatment. However, previous studies are limited in scale and data coverage. Therefore, this study aims to elucidate the distribution of mediastinal lesions, offering valuable insights into this disease. MATERIALS AND METHODS: This multi-center, hospital-based observational study included 20 nationwide institutions...
March 30, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38564919/lung-cancer-among-the-elderly-in-denmark-a-comprehensive-population-based-cohort-study
#12
JOURNAL ARTICLE
Niels Lyhne Christensen, Anja Gouliaev, Sean McPhail, Georgios Lyratzopoulos, Torben Riis Rasmussen, Henry Jensen
OBJECTIVE: Lung cancer primarily occurs in the elderly with a median age at diagnosis in Denmark of 73 years. However, elderly patients are under-represented in clinical trials as well as in screening studies. In this study, we aim to characterize elderly patients with lung cancer and explore the diagnostic intensity, treatment patterns, and survival. METHOD: Patients diagnosed with lung cancer between 2014 and 2017 according to the Danish Cancer Registry, and with clinical information in the Danish Lung Cancer Registry were included...
March 29, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38555809/establishing-mesothelioma-patient-derived-organoid-models-from-malignant-pleural-effusions
#13
JOURNAL ARTICLE
Ashleigh J Hocking, Lauren A Mortimer, Alexandra L Farrall, Prudence A Russell, Sonja Klebe
OBJECTIVES: Pleural mesothelioma is a cancer arising in the cells that line the lungs and chest wall with poor survival and poor response to first-line therapy. Organoid models of cancer can faithfully recapitulate the genetic and histopathological characteristics of individualized tumors and have potential to be used for precision medicine, however methods of establishing patient-derived mesothelioma organoids have not been well established in the published literature. MATERIALS AND METHODS: Long-term mesothelioma patient-derived organoids were established from ten malignant pleural effusion fluids...
March 28, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38531154/malate-a-natural-inhibitor-of-6pgd-improves-the-efficacy-of-chemotherapy-in-lung-cancer
#14
JOURNAL ARTICLE
Mingming Sun, Qi Feng, Qi Yan, Huifang Zhao, Haiyan Wang, Shuai Zhang, Changliang Shan, Shuangping Liu, Jiyan Wang, Hongyan Zhai
OBJECTIVE: Metabolic reprogramming is an important coordinator of tumor development and resistance to therapy, such as the tendency of tumor cells to utilize glycolytic energy rather than oxidative phosphorylation, even under conditions of sufficient oxygen. Therefore, targeting metabolic enzymes is an effective strategy to overcome therapeutic resistance. MATERIALS AND METHODS: We explored the differential expression and growth-promoting function of MDH2 by immunohistochemistry and immunoblotting experiments in lung cancer patients and lung cancer cells...
March 25, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38614069/osimertinib-plus-local-treatment-for-brain-metastases-versus-osimertinib-alone-in-patients-with-egfr-mutant-non-small-cell-lung-cancer
#15
JOURNAL ARTICLE
Takehiro Tozuka, Rintaro Noro, Hideaki Mizutani, Futoshi Kurimoto, Taiki Hakozaki, Kakeru Hisakane, Tomoyuki Naito, Satoshi Takahashi, Namiko Taniuchi, Chika Yajima, Yukio Hosomi, Takashi Hirose, Yuji Minegishi, Tetsuya Okano, Koichiro Kamio, Tomoyoshi Yamaguchi, Masahiro Seike
OBJECTIVES: Osimertinib is a standard treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and is highly effective for brain metastases (BMs). However, it is unclear whether local treatment (LT) for BMs prior to osimertinib administration improves survival in EGFR-mutant NSCLC. We aimed to reveal the survival benefit of upfront local treatment (LT) for BMs in patients treated with osimertinib. MATERIALS AND METHODS: This multicenter retrospective study included consecutive patients with EGFR mutation (19del or L858R)-positive NSCLC who had BMs before osimertinib initiation between August 2018 and October 2021...
March 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38520908/on-the-hispanic-paradox-in-lung-cancer
#16
LETTER
John Rodriguez
No abstract text is available yet for this article.
March 21, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38552545/revisiting-the-lung-cancer-screening-eligibility-criteria-to-promote-equity-for-black-individuals
#17
JOURNAL ARTICLE
Abdi T Gudina, Charles Kamen, Sara J Hardy, Lee Kehoe, Eva Culakova, Ana-Paula Cupertino
BACKGROUND: Early detection using low-dose computed tomography reduces lung-cancer-specific mortality by 20% among high-risk individuals. Blacks are less likely than Whites to meet lung cancer screening (LCS) criteria under both the former and the updated United States Preventive Services Task Force (USPSTF) guidelines. The purpose of this study was to assess racial disparities in LCS eligibility and to propose tailored eligibility criteria for Blacks to enable equitable screening rate between Whites and Blacks...
March 20, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38552544/anlotinib-plus-docetaxel-vs-docetaxel-alone-for-advanced-non-small-cell-lung-cancer-patients-who-failed-first-line-treatment-a-multicenter-randomized-phase-ii-trial
#18
JOURNAL ARTICLE
Xingxiang Pu, Zemin Xiao, Jia Li, Zhijun Wu, Zhongxia Ma, Jie Weng, Maoliang Xiao, Yanhua Chen, Yongqing Cao, Peiguo Cao, Qianzhi Wang, Yan Xu, Kang Li, Bolin Chen, Fang Xu, Liyu Liu, Yi Kong, Hui Zhang, Huaxin Duan, Lin Wu
OBJECTIVES: Given the modest efficacy of docetaxel in advanced non-small cell lung cancer (NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in combination with docetaxel compared to docetaxel monotherapy as a second-line therapy for patients with advanced NSCLC. MATERIALS AND METHODS: In this phase II study, patients with advanced NSCLC experiencing failure with first-line platinum-based regimens were randomized in a 1:1 ratio to receive either anlotinib plus docetaxel or docetaxel alone...
March 18, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38554546/a-pragmatic-guide-for-management-of-adverse-events-associated-with-lorlatinib
#19
REVIEW
Geoffrey Liu, Julien Mazieres, Jan Stratmann, Sai-Hong Ignatius Ou, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J Solomon, Todd M Bauer
Lorlatinib is a brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). In clinical trials, lorlatinib has shown durable efficacy and a manageable safety profile in treatment-naive patients and in those who have experienced progression while receiving first- and/or second-generation ALK TKIs. Lorlatinib has a distinct safety profile from other ALK TKIs, including hyperlipidemia and central nervous system effects...
March 15, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38520909/ex-vivo-drug-testing-of-patient-derived-lung-organoids-to-predict-treatment-responses-for-personalized-medicine
#20
REVIEW
Josephine A Taverna, Chia-Nung Hung, Madison Williams, Ryan Williams, Meizhen Chen, Samaneh Kamali, Vaishnavi Sambandam, Cheryl Hsiang-Ling Chiu, Pawel A Osmulski, Maria E Gaczynska, Daniel T DeArmond, Christine Gaspard, Maria Mancini, Meena Kusi, Abhishek N Pandya, Lina Song, Lingtao Jin, Paolo Schiavini, Chun-Liang Chen
Lung cancer is the leading cause of global cancer-related mortality resulting in ∼ 1.8 million deaths annually. Systemic, molecular targeted, and immune therapies have provided significant improvements of survival outcomes for patients. However, drug resistance usually arises and there is an urgent need for novel therapy screening and personalized medicine. 3D patient-derived organoid (PDO) models have emerged as a more effective and efficient alternative for ex vivo drug screening than 2D cell culture and patient-derived xenograft (PDX) models...
March 14, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.